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RESUMO 
A psoríase é uma doença sistémica com impacto considerável na qualidade de vida dos 
doentes afetados. O seu pico de incidência coincide com a idade reprodutiva da mulher e 
a gravidez acarreta questões desafiantes em relação ao seu tratamento. De facto, tanto a 
saúde da mãe como a do feto têm de ser tidas em linha de conta. Ao decidir sobre o 
tratamento para a psoríase da mulher grávida (ou que pretende engravidar) através do uso 
de terapia farmacológica, é importante ter-se consciência das opções disponíveis e as suas 
repercussões. Assim, nesta revisão sistemática, pretendemos explorar de que forma a 
psoríase pode ser farmacologicamente abordada durante a gravidez, bem como nos casos 
em que a mulher pondera engravidar, de acordo com a informação existente e os possíveis 
efeitos, quer para a mãe, quer para o feto. 
Relativamente aos métodos, foi realizada uma pesquisa usando termos MeSH (Medical 
Subject Headings) relacionados com este assunto, em bases de dados como PubMed, 
MedLine, Cochrane e ScieLO. Foram considerados estudos em humanos e animais, sem 
limite de tempo estabelecido, mas dando preferência às publicações mais recentes. 
A vasta pesquisa realizada permitiu-nos reconhecer que a abordagem da psoríase na 
gravidez constitui um verdadeiramente um desafio. Apesar de existirem várias terapias 
farmacológicas disponíveis para o tratamento da psoríase, desde terapias tópicas a 
biológicas, passando pela fototerapia e terapia sistémica, a gravidez encerra questões 
éticas de suma importância, pelo que uma abordagem farmacológica deverá ser bem 
ponderada. A informação existente em seres humanos é limitada, sendo necessária mais 
investigação nesta temática. Dentro das terapias biológicas, o certolizumab pegol (CZP) foi 
recentemente apontado como sendo um fármaco promissor durante a gravidez, uma vez 
que revelou não ter ou ter mínima passagem através da barreira placentar. 
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ABSTRACT 
Psoriasis is a systemic disease with considerable impact on the patient’s quality of life. Its 
onset collides with women’s reproductive frame time and pregnancy brings challenging 
concerns to its treatment. Indeed, both mother and fetus’ health has to be considered. When 
choosing to treat pregnant women (or those who wish to conceive) affected by psoriasis 
with pharmacological therapy, it’s important to be aware of the disposable options and their 
repercussions. Thus, on this systematic review we aim to explore how psoriasis can be 
pharmacologically managed during pregnancy, or in women considering childbearing, 
according to the current data available and possible effects for both mother and fetus.  
As methods are concerned, we’ve pursued a research using MeSH (Medical Subject 
Headings) terms related with this matter, on data bases like PubMed, MedLine, Cochrane 
and ScieLO. We’ve considered studies in humans or in animals, with no limit in time 
established for the consulted articles. Preference was given to the most recent publications.  
The extensive search performed allowed us to recognise that managing psoriasis during 
pregnancy is quite challenging. Although there are several pharmacological therapies 
available to treat psoriasis, from topical to biological therapies, passing through 
phototherapy and systemic therapy, pregnancy brings ethical concerns and a 
pharmacological approach must be well-thought-out. The data available in humans is 
limited and further investigation in this matter is needed. Within biological therapies, 
certolizumab pegol (CZP) has even been most recently pointed as a possible promising 
approach during pregnancy as this drug has shown no or minimal placental absorption. 
 
KEYWORDS: Dermatologic agents/therapeutic use; Immunosuppressive 
agents/therapeutic use; Pregnancy/ Pregnancy complications/therapy; Psoriais; 
Psoriasis/treatment  
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0- INTRODUCTION 
 
Despite being recognised by its typical cutaneous symptoms, psoriasis consists in a 
systemic disease with complex pathomecanisms, on which environmental, genetic and 
immunologic factors play an influence.1,2,3 This disease is epidemically and socially 
important as it affects 2.5% of the population1, possibly leading to comorbidities and bringing 
major impact on the quality of life of the affected patients.4, 5, 6 
The onset of psoriasis collides with women’s reproductive years.7 Thus, besides the 
expected endocrine and immunological changes during pregnancy, psoriasis brings a 
greater challenge for the maternal body.8, 9 Considering that the course of the disease is 
quite unpredictable during pregnancy, a proper management of this stage of life must be 
wisely weighted, as both mother and the fetus must be considered.5 
As it is difficult to achieve a balance between the advantages and disadvantages that the 
several therapeutic approaches might lead in the context of psoriasis, in this review we will 
present: the pathogenesis of psoriasis; its clinical features and therapeutical options 
available to treat psoriasis and its influence on pregnancy. 
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1-PSORIASIS 
 
Affecting around 2,5% of the population worldwide, psoriasis is broadly recognised by its 
cutaneous features, since it’s commonly identified by the emergence, on the skin, of 
papules and plaques covered with silvery scales.1,2 Nevertheless, the hypothesis that 
psoriasis is a disease restricted to the skin was turned away by the identification of complex 
mechanisms involved in its etiopathogenesis which allowed to define psoriasis as a chronic, 
inflammatory and systemic disease.1,2,3,7 
Psoriasis is influenced by environmental, genetical and immunological factors, and the 
spread of symptoms that go along with this disease can be large.1, 2, 3, 4 Psoriasis may also 
be accompanied by comorbidities characterized by chronic inflammation of different 
degrees.4,10 In fact, patients with psoriasis are under a higher risk of developing arthritis 
(which affects up to 40% of the patients), cardiovascular disturbances, metabolic syndrome, 
diabetes, inflammatory bowel diseases (like Crohn’s disease), and other 
complications.3,4,10,11,12,13 Thus, there’s an impairment on the physical and psychosocial 
functions of these patients which leads us to consider that psoriasis has a negative impact 
on their quality of life and potentially on their long-term survival.5, 6,13 
There are five subtypes of psoriasis described: vulgaris (plaque-type psoriasis), guttate 
psoriasis, inverse psoriasis, pustular psoriasis (either localized or generalized) and 
erythrodermic psoriasis.14,15 
Classically, histological findings consist in acanthosis, hyperkeratosis, parakeratosis and 
expansion of epidermal rete ridges.14,16 There is also an additional number of contorted and 
leaky vessels and an increased inflammatory cell infiltrate in the stratum corneum and 
epidermis (Munro’s microabscesses and Kogoj pustules).4,14,16 Therefore, a crosstalk 
between hyperproliferative keratinocytes, neutrophils, mast cells, dendritic cells and T cells 
induces inflammatory and pro-proliferative circuits, which leads to the development of 
psoriatic lesions.14,17 
The involvement of the immune system in psoriasis is widely accepted.18,19 An accurate 
characterization of the immune pathways underlying the psoriatic phenotype allowed the 
IL-23/IL-17 axis to be considered the main immune pathway in psoriasis pathogenesis.17 
Several factors induce the activation of mDCs (myeloid dendritic cells) with consequent IL-
23 production. Indeed, keratinocytes arrange TSLP; fibroblasts produce TNF-α and IL6; 
pDCs (plasmacytoid dendritic cells) yield IFN-α, and natural killer T cells launch TNF-α and 
IFN-γ, which causes IL-23 to produce IL-20, nitric oxide and TNF-α.20 Therefore, IL-23 
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stimulates specially T cell subsets (like T 17 and T 22) but also mast cells, neutrophils, and 
ILC3, leading to the secretion of IL-17 and IL-22.17,20 High levels of IL-17 are expressed in 
lesioned psoriatic skin. Keratinocytes respond to IL-17 producing AMPs, chemokines (like 
CCL20, and CXCLs) and proinflammatory cytokines. CCL20 drives IL-17 to recruit IL-17+ 
T cell subtypes (Tc17, Th17 and γδ T cells) and mature mCDs.17,20. IL17 can also stimulate 
autoantigen production and neutrophil recruitment and survival.17,21Apart from the IL-23/IL-
17 axis, strong evidence also suggests the contribution of multiple T-cell subsets (Tc1, Th1, 
Th9, Th21 and Th22) on the establishment of psoriasis.22-25 Without undervaluing fibroblasts 
and endothelial cells role, the most preponderant tissue response is attributed to 
keratinocytes.17,20 T-cell cytokines are responsible for acanthosis, as they induce 
proliferation and activation of keratinocytes, leading to the production of chemokines and 
other pro-inflammatory molecules (like IL-1β, IL-6, TNF-α and anti-microbial peptides), 
which amplifies immune cell recruitment and sustains inflammation and lesion in the 
skin.12,17,26 
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2-PSORIASIS AND PREGNANCY 
 
The first symptoms of psoriasis usually occur between the second and the fourth decades 
of life and the diagnose is established, in average, at the age of 28.7,27 So, the onset of the 
disease collides with women’s reproductive years, pointing out that it is not uncommon to 
see psoriasis in pregnant women.7,27-29 Thus, this stage of life is enhanced by the creation 
or maintenance of relationships.30  So, besides the psychological burden possibly present 
in women diagnosed with psoriasis, it’s important to reveal that this disease may also bring 
negative consequences for their partners.31-34 Indeed, they also might feel their quality of 
life being questioned, as psoriasis might bring negative impact on the couple’s 
relationship.30,31 When considering pregnancy, couples should so be aware of the possible 
consequences both for mother s for the fetus about the implications of this disease and it’s 
treatment options.5,35,36 
Pregnancy entails an inimitable challenge for the maternal organism, as it involves 
remarkable endocrine and immunological changes.8,9 The course of psoriasis during 
pregnancy is quite unpredictable.5 Most women experience an improvement of their 
symptoms, and some even keep a steady state, but there are cases where there’s an 
exacerbation of the disease.5,27,36,37 
The impact of maternal psoriasis on the developing fetus is an aspect of great concern.38 
Studies pointed several adverse fetal outcomes, like spontaneous abortion, prematurity, 
macrosomia, disturbances related to weight (from large-for-gestational age to low birth 
weight) and a higher need for caesarean delivery. However, these associations were 
inconsistent among these studies, resembling that further investigation in this area is 
needed.38 
The fact that severe disease may have a negative impact on both mother and fetus, 
highlights the importance of measuring equally the risks of treating or not treating 
psoriasis.35 
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3- MANAGING PSORIASIS DURING PREGNANCY 
 
3.1- GENERAL CONSIDERATIONS 
The first trimester matches the pregnancy’s period with the highest chance of teratogenicity 
induced by drugs.35 However, even when under treatments with eventual teratogenic 
effects, couples’ compliance with pregnancy prevention is considerably poor.35 Counselling 
prior to pregnancy is then an aspect of major importance as it provides not only education 
but also the timely decision on the most adequate therapeutic regimen having in view the 
possibility of pregnancy.35,39 Also, in order to minimize possible flares of psoriasis during 
pregnancy, the ideal should be, if conceivable, to optimize the control or even to induce 
remission of the disease before conception.29 
During pregnancy, the decision of treating psoriasis and how to manage the treatment 
options demands a careful thought, as both mother and the fetus’ health must be 
considered.5,40 The goal is to reach the best possible disease control, but it must be taken 
into account not only the extent of the disease on the affected pregnant women, but also 
the principal of not affecting the fetus in an undesired way.5,41 However, due to obvious 
ethical constraints of performing clinical trials on pregnant women, there is limited data on 
this matter.5 Most information comes from inadvertent fetal exposure due to treatments for 
psoriasis on women who were unaware of their pregnancy.40,41  
In pregnant women with mild psoriasis or in those experiencing improvement of the disease 
during pregnancy, discontinuation of medication can be an option. However, this might not 
be the best choice for those experiencing severe psoriasis. So, it’s mandatory to 
acknowledge the risks for pregnancy for each kind of treatment available.40,41 
Concerns on the use of medication during pregnancy were highly enhanced since the 
1960s, when thalidomide showed deleterious effects on the fetus.42 Consequently, further 
investigation on drugs with teratogenic potential has been pursued and heightened 
regulation has been placed by governmental agencies.43 Further data on animals and 
humans has been presented and in order to summarize the information obtained, 
classification systems have been established in order to help health professionals.44 
A source of information on safety on using certain drugs during pregnancy is given by United 
States Food and Drug Administration (FDA). This system emerged in 1979 and was based 
in the classification of drugs into one of five letter system: A, B, C, D and X. 44,45 Each 
category relies on animal studies, human and data and information of risk of adverse effects 
against potential benefits of the drug, as listed in the following table (table I):45 
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A Controlled clinical trials in females failed to show a risk to the fetus in the first trimester, 
and the possibility of harm to the fetus appears remote 
B Either animal studies did not show a risk to the fetus and no controlled human studies 
are available, or animal studies showed an adverse effect on the fetus but well-
controlled clinical trials in pregnant females have failed to demonstrate a risk to the 
fetus 
C Animal studies have shown teratogenic or embryocidal effects, but there are no 
controlled clinical trials in females, or no studies are available in either animals or 
humans 
D Positive evidence of fetal risk exists in humans, but benefits in certain situations may 
justify the use of the drug despite its risks (e.g., life-threatening situations or in cases 
where safer drugs cannot be used or are ineffective for treatment of serious diseases) 
X Studies in animals or humans have shown fetal abnormalities or there is evidence in 
humans of fetal risk, or both, and the risk outweighs any possible benefit 
 Table I - US-FDA pregnancy risk category definitions.45 
 
To guide treatment of psoriasis during pregnancy, this categorization into letters has been 
helpful in clinical practise as replacing markers of risk stratification.46 However, this system 
has proven to be often confusing, being overly simplistic and a limited way to reflect the 
available information.44,47 So, using this system may lead to false assumptions about drugs 
based on their category.44 According to this, in 2015 FDA introduced a new Pregnancy and 
Lactation Labelling Rule (PLLR), which replaces the letter rating system by narrative-based 
labelling requirements.46,48,49 So, the application of this new system has been done by 
phases for existing medications, but drugs which have been approved after June of 2015 
must necessarily fulfil the new PLLR.43,49 For these drugs, it won’t be attributed a safety 
category as they were replaced with individualized narrative summary of each drug.49 
With the establishment of PLLR being so recent, at the present moment there are on the 
market therapeutics which are still attached to the previous categorization system, along 
with other drugs that already follow the new system given by PLLR.45 Taking these aspects 
in consideration, on this review, reference to FDA categorization system will be made, if 
applicable, as well as other important data existing on use for each therapeutic. 
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Drugs will then be approached in this review according to their profile in terms of their 
adverse effects on pregnancy. 
 
3.2- TOPICAL THERAPIES 
The first line treatment options during pregnancy are topical therapies.29,39,50 When used 
judiciously, there is no substantial systemic absorption, and levels high enough to cause 
adverse effects on the fetus won’t be reached. However, overdose increases the risk of 
teratogenicity.41 
Provided that the disease is limited, priority should be given to emollients and moisturizers 
as they are well tolerated, lacking significant adverse outcomes.50  
Topical corticosteroids are known as the pillars of dermatotherapeutics.51,52 When used 
appropriately (with the least potency required and judicious monitorization of duration and 
amount of application), they are assumed as safe for childbearing women.51,53 FDA 
classifies topical corticosteroids as category C and although there is no risk of any fetal 
abnormality, it’s stated that preference should be given to mild to moderate potency topical 
corticosteroids.5,51,53  Potent or super potent topical corticosteroids should be used as 
second-line therapy as the current evidence points they are associated to a higher likelihood 
of low birth weight, particularly for large amounts. On these cases, meticulous obstetric care 
is mandatory.51,53  
Topical calcineurin inhibitors like tracolimus are occasionally applied on small areas of 
sensitive skin on intertriginous areas (for example: genitals and face).5,50 It is stated that, 
systemically, tracolimus can cross into the fetal circulation in humans and it has been related 
to low birth weight, prematurity, transient neonatal hyperkalaemia and renal dysfunction.54-
60 On its hand, topical use of calcineurin inhibitors is poorly associated with systemic 
absorption and so this application route is expected to be safe.35,61,62 However, further 
information on topical use of this drug in pregnancy is required and so FDA classifies topical 
calcineurin inhibitors as category C.5,35 
Within topical agents, anthralin (or dithranol)’s use is not currently approved during 
pregnancy, as there’s not enough data concerning humans or animals.35,50 FDA has 
assigned category C for this drug and it’s pointed that it’s use must be stopped 4 weeks 
before conception.35,63 
There is also limited data regarding the use of salicylic acid during pregnancy and FDA 
assigned this drug as pregnancy category C.35,50 However, it is recognised that moderate 
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amounts or higher concentrations can be absorbed systemically and there are studies 
pointing effects due to prenatal exposure.64-66 Therefore, their use must be dodged.35 
Systemic absorption may also occur on using calcipotriol, which is an analogue of vitamin 
D3.5,41,67,68 There are no studies in humans reporting teratogen effects during 
pregnancy.5,50,61,69 However, there are animal studies showing a higher incidence of sketal 
abnormalities and incomplete ossification of forelimb phalanges and pubic bones related to 
the administration of calcipotriol.35 So, despite topical use of the recommended dosage is 
considered safe, caution is required, as there is no human data available at the 
moment.5,50,61,69 FDA classifies calcipotriol as category C.5 
On its hand, tazarotene, a topical retinoid, has trifling systemic absorption and combination 
with this drug may improve efficacy on treating psoriatic lesions, diminishing safety and 
tolerability concerns.5,35,52,70,71 Nevertheless, it’s risks for the developing fetus are still 
unknown as there is limited human data.35,72 So, their use must be avoided during 
pregnancy and FDA assigned this drug as category X for pregnancy.5,32,43 
As far as coal tar is concerned, the number of cases described are low, but the reports of 
spontaneous abortions, congenital disorders and teratogenicity found in animal studies 
raise major concerns.32,61 Thus, although there are not enough studies proving teratogenic 
effects in humans, coal tar is not recommended during pregnancy and has no FDA 
pregnancy category.5,32,50,69,73  
 
3.3- PHOTOTHERAPY  
3.3.1-  UVB/Narrowband UVB 
In the presence of moderate to severe psoriasis, topical therapy might not be enough.74 
Narrow-band ultraviolet B (NB-UVB) is regarded as a first-line treatment when a systemic 
approach is needed5. This therapy holds no FDA pregnancy category but has been 
successfully used in pregnancy.5,74,75 Recurrence to NB-UVB has shown no fetal 
abnormalities and premature deliveries aren’t documented so far.74,75 However, there are 
concerns regarding the decreasing of serum folate levels with UV light exposure. This 
deficiency rises the risk of fetal neural tube defects with hyperthermia and so, overheating 
must be avoided, especially during the first 28 days of gestation.49,74,75,76 Therefore, the 
importance of monitoring levels of folic acid during this treatment acquires greater 
relevance, along with proper supplementation with this vitamin.35,77  
Broadband UVB is a slightly less effective alternative, but it can be used if NB-UVB is not 
available.36 
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3.3.2- Psoralen Plus UVA 
To increase skin reactivity to ultraviolet A (UVA), psoralen is orally administrated to patients 
who are under treatment with this phototherapy. PUVA (psoralen plus UVA) hasn’t revealed 
to be unsafe, however this drug is listed as FDA pregnancy category C.5,78 As a matter of 
fact, psoralen has a theoretical risk of teratogenic and mutagenic effects, as when in 
presence of UVA this drug inhibits DNA synthesis and cell division.78 This way, PUVA must 
be avoided during pregnancy.5 
 
3.4- SYSTEMIC THERAPY  
3.4.1- COMMON SYSTEMIC DRUGS/ ORAL SYSTEMIC THERAPY 
3.4.1.1- Methotrexate 
FDA classifies Methotrexate as category X, that is, it’s absolutely contraindicated during 
pregnancy or in those planning pregnancy as this agent has proven to be abortifacient, 
teratogenic and mutagenic.28,50,76 Discontinuation of methotrexate is actually recommended 
three months prior to conception as a “washout” period is advisable.69,79 The importance of 
prenatal counselling is also highlighted by the association of this drug with disturbances in 
spermiogenesis which interfere with chromosomic and mobility alterations on the sperm. 
Maternal exposure during pregnancy to this drug has an association with congenital 
malformations, with birth defects in several systems such as central nervous system, 
gastrointestinal and cardiopulmonary,80-82 which can even include the methotrexate 
syndrome.83-87 This syndrome is characterized by intrauterine growth retardation, deficient 
ossification of the calvarium, underdeveloped supraorbital ridges, small and low-set ears, 
limb anomalies and developmental delays.82,88 
3.4.1.2- Acitretin 
The risk of using acitretin, a second-generation retinoid, during pregnancy is considered 
very high.32,76 This drug is listed as a category X by FDA due to its teratogenic effects being 
the first trimester of pregnancy the period of higher risk of spontaneous abortion or 
congenital malformations.89  
Fetal exposure to acitretin may lead to a syndrome called “retinoic acid embryopathy”, which 
is characterized by malformations of the central nervous system, thymic structures, and 
even craniofacial or cardiac alterations.89-91 
It is recommended to discontinue acitretin 2 years before conceiving a child,92,93 which 
makes acitretin an impractical therapy for most women who have reproductive purpose.39 
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 3.4.1.3- Ciclosporin 
Ciclosporin can cross the placental blood barrier and may achieve up to 50% of the maternal 
plasma concentration.94 Contradicting possible expectations, there is no report of 
teratogenic effects in animals or humans and so ciclosporin is considered by FDA as 
category C.5,28 Nevertheless, there are few studies among pregnant patients with 
psoriasis.95 Most information comes from patients who needed transplantation and the 
association between the low birth weight and prematurity reported can’t be directly linked 
to the use of this drug as the health status of these patients may play an influence in the 
results observed.5 
3.4.1.4- Apremilast 
At the present, there is no human data concerning the use of apremilast during 
pregnancy.35,40 However, betake of this drug in animals has led to dose-related abortions 
and reduced birthweight.35 This way, apremilast is currently contraindicated in pregnancy, 
being listed as pregnancy FDA category C.35,43 
 
3.5-BIOLOGICAL THERAPY 
Due to their condition and underlying ethical reasons, pregnant patients with psoriasis are 
usually excluded from clinical trials. This way, there is an obvious gap on large and 
controlled studies concerning TNF-alfa (TNF-α) inhibitors and newer biologic agents, such 
as IL-12/23 inhibitor (ustekinumab) and IL-17 inhibitors (like secukinumab and 
ixekinumab).96 
Most monoclonal biologics behave like maternal antibodies, but they don’t cross the 
placenta in an equal way.35 On choosing biological therapy during pregnancy, it should be 
kept in mind the immunosuppression that can be induced on both mother and the fetus.5 In 
early pregnancy, possibility of teratogenicity and malformations must also be considered. 
Particularly for the fetus, it should be regarded not only the possibility of 
immunosuppression but also the possible influence in the immune development, being the 
critical period from the third trimester up to 6 months of age as a neonate.35 
Most data on biological therapy comes from animals, small retrospective studies, case 
reports or, most recently, from surveillance registries pointing outcomes from cases of 
pregnant women under treatment with biological agents.96 Despite the risk of bias that these 
registries might suffer and the absence of well-controlled trials, the increasing amount of 
literature suggests that biologic agents can be used for treating psoriasis during 
pregnancy.96-98 
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3.5.1- TNF-α INHIBITORS 
Antibodies to tumor necrosis factor α (anti-TNF) are the most frequently biological agents 
used to treat inflammatory diseases like rheumatoid arthritis and inflammatory bowel 
disease.96,99 So, most data of their use in pregnancy comes from rheumatology and 
gastroenterology literature.96 
It’s known that maternal IgG antibodies can cross the placenta by simple diffusion. 
However, active transport of these immunoglobulins can be established via Fc receptors on 
the syncytiotrophoblast, which begins in the second trimester of pregnancy and rapidly 
increases over the third trimester.28,43  
The transference antibodies anti-TNF across the placenta is done by the binding between 
they’re Fc-region to the neonatal Fc receptor and so their use may bring fetal or neonatal 
effects.99,100 This way, use of anti-TNFs has to be well thought out during pregnancy.99 
Unlike other anti-TNFs, certolizumab pegol lacks an Fc-region and for this reason this drug 
will be discussed separately on this review.99 
3.5.1.1- Etanercept, Infliximab and adalimumab  
Conflicting data about the use of anti-TNF drugs has been published and the present 
information available is still limited.96 Even the relationship between each TNF-α inhibitor 
and the risk of malignancy is still in debate.101 
Investigations point out that cytokine TNF-α may help preventing structural anomalies 
during embriogenisis.101-103 Obviously, this concept raised concerns about the impact of 
TNF-α inhibitors on the fetus.96 However, as far as etanercept, infliximab and adalimumab, 
are concerned, no substantial differences were found in the number of miscarriages, live-
born infants or congenital defects when compared with the general population.101 These 
drugs are considered pregnancy category B by FDA.43 
Unintended exposure to etanercept and infliximab is considered a low risk at least from 
conception till the second trimester of pregnancy.35,43,104 Adalimumab even has no data 
pointing teratogenic, embryotoxic or fetotoxic effects.105 
One aspect with major importance is that live vaccines MMR (against measles, mumps and 
rubella), oral polio, rotavirus and BCG (with Bacillus Calmette–Guérin) should be 
administrated with extreme caution in cases where a fetal exposure to TNF-α inhibitors 
occurred.35 There is even a case report verifying the death of a child from disseminated 
Bacillus Calmette–Guérin after administration of BCG at three months of age whose mother 
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received infliximab during pregnancy.106 The current endorsement is to delay the 
administration of live vaccines until the age of 6 to 12 months old.35 
On the maternal side, there’s a fundamental concern to consider: the risk of reactivation of 
tuberculosis, especially in areas where this disease is endemic. It’s known that TNF-α is 
important to the integrity of the granulomas moulded in prior infection, and so, every patient 
should go under tuberculosis screening before initiating TNF-α inhibitors.101  
Approaching infliximab in a particular way, it’s known that this drug can lead to an infusion 
reaction (characterized by esophageal atresia, tracheophageal fistula, anal atresia and 
vertebral, cardiac, renal and limb anomalies).43 The probability of its occurrence can be 
reduced by co-treatment with methotrexate. However, as discussed previously on this 
review, methotrexate is contraindicated during pregnancy. Being so, women tend to choose 
stopping infliximab at this stage of life. For those women, disruption of this drug is 
counselled 50 days prior to conception.35,101 
3.5.1.2- Certolizumab Pegol  
Certolizumab pegol (CZP) is the most recent anti-TNF drug receiving approval in the Europe 
and the United States of America for the treatment of psoriatic arthritis.107 Thanks to its 
unique structure without the FC portion, by which CZP is distinguished from other anti-
TNFs, this drug is known by its lack of late active placental transfer.99 Pointing an advantage 
of its use, pregnancies with exposure to certolizumab pegol haven’t shown so far clear signs 
of fetal harm.108 That can be explained with the fact that IgG is the only antibody that can 
cross the placental barrier between mother and the fetus by a specific FC portion. Without 
this portion, CZP is expected to cause lower fetal exposure when compared with other anti-
TNFs, as it’s transference throughout placenta barrier is compromised.61 
According to this idea, an update on the pharmacovigilance database of pregnancy 
outcomes has been performed by Clowse et. al (2018) on women affected by chronic 
inflammatory diseases. Although this study wasn’t elapsed specifically on psoriasis, it’s 
importance relies on the fact that it’s the most recent and also the largest cohort of pregnant 
women exposed to an anti-TNF drug, CZP. Considering the outcomes available from the 
use of this drug, the large majority were live births (85,3%), with no suggestion of teratogenic 
effects or increased risk of fetal death, when compared to the general population. Indeed, 
most of these pregnancies were exposed to certolizumab pegol during the first trimester 
and it wasn’t found any link with major congenital malformations.108 This information collides 
with other prospective studies.104,109,110 
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As the exposure of pregnant women to CZP during the third trimester is concerned, a 
prospective study named “CRIB” concluded there was no or minimal placental transfer of 
this drug to their infants.111 Although further information is needed, this evidence points out 
that as well as what’s been described for the first trimester (when the organogenesis 
primarily takes place), there is a lack of fetal exposure in utero to CZP in the third 
trimester.108,111 Despite further studies are lacking, treatment with CZP is recommended 
throughout pregnancy when control of disease activity is needed.111,99 This drug is 
considered as pregnancy category B by FDA.108 
3.5.2-IL-12/23 Antagonists 
3.5.2.1- Ustekinumab 
Ustekinumab acts by blocking IL22 and IL-23 cytokines.40 Being a large molecule, this 
human monoclonal antibody is expected to be transferred to the fetus in a modest way until 
the late second or even until the early third trimesters.40,61 
Animal studies report no adverse effects for the fetus or offspring after exposure to 
ustekinumab and this drug is considererd as category B by FDA.43,112 However, there is 
limited data on humans and this way this drug should be discontinued during 
pregnancy.5,35,61 Discontinuing this drug one year before conception is advised.113  
3.5.3- IL-17 ANTAGONISTS 
Secukinumab (FDA pregnancy category B) and Ixekinumab (no FDA category assigned), 
target cytokine IL-17.5 More specifically, IL-17A is targeted by brodalumab (no FDA 
category assigned). Currently, there is no data on the safety of the use of these agents on 
pregnancy on humans.5,35 This way, treatment with these biological agents should be 
avoided during pregnancy.5,35 
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4- DISCUSSION 
 
The establishment of psoriasis has its incept between the second and the fourth decades 
of life, matching women’s reproductive years.7,25,29 Being known by its impact on the quality 
of life, psoriasis brings particularly to this stage of life a major concern: the patient’s self-
confidence.114 
Being young adulthood characterized by the creation and/or maintenance of relationships 
with partners,114 women with psoriasis often suffer from stigma and see themselves in a 
restrictive way of living.34,114-117 Even for these women’s partners, a negative influence in 
their quality of life is assumed as an existing reality118. So, in the occurrence or when 
considering pregnancy, a discussion taking in account the several options of 
pharmacological therapy acquires even further relevance.114 
The available treatments for psoriasis must be adapted to each clinical case, as its course 
during pregnancy is unpredictable.5 Most women experience an improvement of the 
disease, but an exacerbation of the symptoms may occur.5, 28, 36, 53 The impact on the 
developing fetus is also a matter of great concern, as it can be affected not only by 
maternal’s psoriasis but also by the pharmacological therapy disposable in the market.35,38 
Therefore, we aimed with this review to search for the available data on the safety of drugs 
used to treat psoriasis and its effects during pregnancy. We’ve found it to be is rather 
challenging, as there are possible effects on both mother and fetus.5,40,41 Furthermore, there 
is limited data regarding safety, during pregnancy, of the disposable medications.5 As 
obvious, there are ethical constraints on performing clinical trials on pregnant patients and 
so most information comes from inadvertent fetal exposure or from animal studies.5,40,41,119 
Limited data among humans urges from a rather plausible concern: inappropriate use of 
drugs may lead to excruciating consequences, as seen with use of thalidomide, back in the 
1960s.43 Its teratogenic effects were so remarkable that scientific community felt the need 
to regulate use of drugs during pregnancy.43,119 So, sources of information on safety 
emerged as attempts to guide doctors when prescribing certain drugs.119 One of that 
sources is FDA, and we’ve recurred not only to FDAs new labeling system but also to the 
previous five-letters categorization system, to allow a better view on the existing information 
available on the drugs approached in this review.46,43,48,119  
Among the treatment options available for psoriasis during pregnancy, topical therapies are 
considered the first line therapies for psoriasis during pregnancy, as no substantial 
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absorption is expected to occur.39,29,41,48,50 Emollients, moisturizers and corticosteroids 
should be given priority as they lack significant outcomes.50-52 Because potent or super 
potent topical corticosteroids are more likely to cause low birth weight, preference should 
be given to mild to moderate corticosteroids.5,50-53 As far as calcineurin inhibitors, salicylic 
acid and calcipotriol are concerned, their use must be dodged as further information on their 
use in humans is lacking.5,35,61,50,69 Still in the category of topical agents, it is important to 
notice that anthralin, tazarotene and coal tar are not recommended during pregnancy. 
5,35,43,50,61,71,69,73 On its hand, although there is no safety categorization by FDA to coal tar, 
the reports of teratogenic effects found in animals makes it a drug to avoid during pregnancy 
in humans.5,35,50,69,73 As for anthralin and tazarotene, FDA assigns these drugs as pregnancy 
safety category X.5,35,43,63. 
When a systemic approach is needed, phototherapy with NV-UVB is regarded as first-line 
treatment for psoriasis during pregnancy,7,50,75 as the only side effect documented so far is 
the diminishing of serum folate levels because of the UV exposure, that can be outdated by 
monitoring its levels and appropriate supplementation with this vitamin.40,49,75-77 Otherwise, 
PUVA must be avoided because of its theoretical risk of teratogenic and mutagenic effects, 
holding a C category on the FDA categorization system for pregnancy.5,78 
As systemic therapy is concerned, methotrexate and acitretin are listed as FDA pregnancy 
category X, being absolutely contraindicated during pregnancy as they are related to 
teratogenic effects.25,50,76,89 Although apremilast holds a category C on FDA categorization 
system, it is also contraindicated during pregnancy because in animals this drug has led to 
abortions and reduced birthweight.35,43  Otherwise, ciclosporin, FDA category C, emerges 
as possible alternative if a systemic approach is needed, as there are no reports of 
teratogenic effects in animals or humans.5,25  
Most recently, a better understanding of the immune pathways involved in psoriasis allowed 
the development of biological agents which target increasingly specific cytokines related to 
psoriasis.1 Examples of biological therapies are anti-TNFs (etanercept, infliximab, 
adalimumab and CZP), IL-12-23 inhibitor ustekinumab and IL-17- inhibitors (secukinumab 
and ixekinumab).96  
Conflicting data has been published about anti-TNF drugs etanercept, infliximab and 
adalimumab (classified by FDA as B category for pregnancy safety) and further data is 
lacking.43,96 However, unintended exposure to etanercept and infliximab, from conception 
and until the second trimester of pregnancy, is faced as a low risk for the fetus.35,43,104 In the 
case of adalimumab, there is even no data pointing adverse effects for the fetus.105 
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Along with the approached anti-TNF drugs, ustekinumab also holds an FDA category B. 
Nevertheless, this human monoclonal antibody is expected to be transferred to the fetus in 
a modest way until the late second or even until the early third trimesters and so it’s advised 
to be discontinued one year before conception.40,61,113 
As IL-17 inhibitors secukinumab (FDA category B) and ixekinumab (no FDA categorization) 
are concerned, it’s stated these drugs must be avoided during pregnancy due to lack of 
further safety information.5,35 For brodalumab, which targets IL-17-A, it seems to be a 
promising ally for the treatment of psoriasis when combined to an anti-TNF drug, again, 
lacking further data on pregnant women.120 
Thus, underlined with the use of biological therapy, the concept that immunosuppression 
can be induced on both mother and the fetus has been globally considered, and even a 
possible influence on the development of the fetus immune system is mentioned.5,35 
However, recent findings have shown that this risk might not be present or be minimal in 
the case of CZP, an anti-TNF drug, because of its lack of an FC-region in its structure. So, 
this drug is not expected to cross the placental barrier and there are no signs pointing 
harmful effects on the fetus, which is quite promising.121-124 Studies relating more specifically 
the use of CZP in pregnant women are lacking.122 
Overall, the increasing amount of literature is in favor of recurrence to biological 
therapies.96,97,98 However, further investigation is needed and pregnant women, for ethical 
reasons, can’t be a part of controlled trials, which can be rather challenging when choosing 
a pharmacological approach for psoriasis.43 
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5- CONCLUSIONS 
 
The onset of psoriasis collides with women’s reproductive years and brings a major impact 
for pregnant women and their partners.7,25,28,29 
Facing psoriasis during pregnancy can be rather challenging as we must regard both 
mother and fetus’ health.5 So, we aimed to acknowledge how psoriasis can be managed 
during pregnancy. As approached, several studies have been pursued to evaluate the best 
disposable pharmacological therapies options for psoriasis when pregnancy occurs, or for 
those who wish to conceive.35,38  
Pre-counselling before pregnancy would be the ideal situation in order to choose, in a more 
adequate way, the most appropriate drug for each clinical case. Furthermore, as seen in 
this review, certain drugs should be stopped even before conception.35 However, we must 
keep in mind that only a few couples resort to medical counseling before pregnancy and 
usually the settings on the medication are done when women are already aware of their 
pregnancy.35 
Nowadays, several pharmacological treatments are available to treat psoriasis: topical 
therapy, phototherapy, systemic therapy and biological therapy. The approach of each 
different therapeutic group pursued on this review enhanced that further data on this matter 
is lacking.  
Recent researches on the psoriasis-signature cytokines that are underlying the 
establishment and worsening of psoriasis allowed a better understanding on the pathways 
on which different biological therapeutic might be helpful. A promising breaking point on the 
way pregnant women with psoriasis are treated might be on recent findings about CZP. This 
biological drug has sown no or minimal placental transfer and this aspect might lead to a 
new horizon on the reach of safer pharmacologic offers to fertile age women with psoriasis. 
As a final comment, and given the limited data available, we stand out the importance of 
deeper studies on this matter, provided with the most adequate registries and data available 
in context of pregnancy in women with psoriasis. In this review we’ve attempted to do that 
recurring to the FDA categorization system for pregnancy. It was rather notorious in this 
review the importance of the new labeling system established by FDA since 2015. The old 
five-letter categorization system to which we have resorted for therapies available on the 
market before 2015 revealed to be, as expected, quite simplistic and contradictory. As an 
example, we’ve described drugs which belong to the same safety category for pregnancy, 
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but there are contradictory demandings on their use during pregnancy, which is quite 
confusing. This way, we conclude that the attempts of giving guidance for clinical 
practitioners have huge importance.  
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